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ABSTRACT: The prevalence of infections caused by metallo-β-lactamase (MBL)
expressing Gram-negative bacteria has grown at an alarming rate in recent years.
Despite the fact that MBLs can deactivate virtually all β-lactam antibiotics, there are as
of yet no approved drugs available that inhibit their activity. We here examine the ability
of previously reported thiol-based MBL inhibitors to synergize with meropenem and
cefoperazone against a panel of Gram-negative carbapenem-resistant isolates expressing
different β-lactamases. Among the compounds tested, thiomandelic acid 3 and 2-
mercapto-3-phenylpropionic acid 4 were found to efficiently potentiate the activity of
meropenem, especially against an imipenemase (IMP) producing strain of K. pneumo-
niae. In light of the zinc-dependent hydrolytic mechanism employed by MBLs,
biophysical studies using isothermal titration calorimetry were also performed, revealing
a correlation between the synergistic activity of thiols 3 and 4 and their zinc-binding
ability with measured Kd values of 9.8 and 20.0 μM, respectively.
KEYWORDS: antibiotic resistance, metallo-β-lactamase, MBL inhibitor, zinc binding, synergy
Resistance to β-lactam antibiotics poses a serious threat tohuman health. The enzymes responsible for such resistance
are the β-lactamases and are especially prevalent among Gram-
negative bacteria.1,2 These enzymes are divided in two classes:
the serine β-lactamases (SBLs), which hydrolyze beta-lactam
rings by a serine nucleophile in their active site, and the metallo-
β-lactamases (MBLs) whose mechanism relies upon the
presence of one or two active site zinc ions.3 These zinc ions
stabilize a nucleophilic hydroxide species that is believed to be
the active agent in the hydrolysis of the β-lactam ring leading to
antibiotic inactivation. The best-studiedMBLs include the NDM
(New Delhi metallo-beta-lactamase), VIM (Verona integron-
encoded metallo-β-lactamase), and IMP (imipenemase) en-
zymes which collectively exhibit a broad substrate specificity and
hydrolyze antibiotics from all known beta-lactam classes.4
The global concern relating to antibiotic resistance has led to a
number of different strategies aimed at addressing the problem.
One such approach involves the coadministration of antibiotic
adjuvants capable of maintaining the activity of existing
antibiotics.5 This strategy is widely effective in treating infections
due to bacteria that express SBLs. Clinically relevant SBL
inhibitors include clavulanic acid, sulbactam, tazobactam, and
avibactam which effectively protect β-lactam antibiotics from
inactivation when administered as combination therapies. By
comparison, there are no clinically used MBL inhibitors available
for use in addressing the growing threat posed to the β-lactam
arsenal by these enzymes.
Attempts to identify inhibitors of the MBLs have revealed a
number of compound classes that display promising activities
when tested using in vitro enzyme inhibition assays.6 Such
compounds include small molecules that contain functionalities
often associated with zinc binding such as thiols, dicarboxylates,
hydroxamates, aryl sulfonamides,N-arylsulfonyl hydrazones, and
tetrazole-based compounds.3,7,8 Among the known MBL
inhibitors, sulfur-containing small molecules containing either a
free thiol or a sulfur atom masked as a heterocycle9,10 are among
the best characterized.3,7,11−15 Structures as simple as mercapto-
acetic acid and mercaptopropionic acid have been shown to be
effective inhibitors of the IMP-1 enzyme (Ki = 0.23 and 0.19 μM,
respectively).16 Follow-up studies identified higher analogs of
mercapto-carboxylic acids including 2-arylmethyl-2-mercapto-
acetic acids and their thioesters as potent MBL inhibitors with
IC50 values in the low-nanomolar range.
17 Similarly, thioman-
delic acid was found to be a broad-spectrum inhibitor of different
MBLs including BCII (Ki = 0.34 μM), IMP-1 (Ki = 0.029 μM),
IMP-2 (Ki = 0.059 μM), and VIM-1 (Ki = 0.230 μM),
18 and 2-ω-
phenylpropyl-3-mercaptopropionic acid has been reported as
potent inhibitor of VIM-2 (Ki = 0.220 μM).
19,20 Other examples
of structurally similar MBL inhibitors include compounds
containing a free thiol with a neighboring carbonyl functionality
such as α-mercaptoacetophenone,21 thiosalicylic acid,18 and
interestingly, the dipeptide drug captopril which is used in the
treatment of hypertension.22 The inhibitory activity of these
molecules is attributed to the ability of the thiol group to chelate
the zinc ion present in the MBL active site as supported by
several X-ray crystallography studies.21,23−26
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The inhibitory activity of thiol-containing small molecules
against clinically relevant MBLs in vitro prompted us to conduct a
series of antibacterial assays to evaluate the synergistic activity of
such compounds with the representative β-lactams meropenem
and cefoperazone. To do so, the sensitizing effects of thiols 1−5
(Figure 1) on the activity of meropenem and cefoperazone were
assessed against a panel of Gram-negative bacteria expressing
various β-lactamases. The stability of the thiols was also assessed
under the assay condition employed, and isothermal titration
calorimetry (ITC) was used to measure the zinc-binding affinity
of the most synergistically active compounds.
■ RESULTS AND DISCUSSION
Thiols 1−5 were initially tested alone for antibacterial activity
against a panel of carbapenem-resistant Gram-negative patho-
gens expressing MBLs including NDM, VIM, and IMP or SBLs
such as KPC-2 and OXA-48. These studies revealed that none of
the thiols inhibited bacterial growth at the highest concentration
tested of 64 μg/mL. With the exception of P. aeruginosa M-120,
which was susceptible to meropenem, all of the MBL-expressing
strains used in our study exhibited resistance to both meropenem
and cefoperazone with MIC values ranging from 8 to >256 μg/
mL. For use as a reference MBL inhibitor known to synergize
with β-lactam antibiotics, we turned to the work of Migliavacca
and co-workers who reported a zinc chelating mixture of EDTA
and 1,10-phenanthroline as being synergistic with imipenem to
prevent growth of MBL-expressing strains of Pseudomonas
aeruginosa.27 We found that the EDTA/1,10-phenanthroline
mixture was similarly effective in lowering the MIC of
meropenem and cefoperazone against the MBL-expressing
strains used in our study (Table 1). Also, and as expected, the
EDTA/1,10-phenanthroline mixture showed no synergistic
effect with meropenem against the two SBL-expressing strains
also evaluated.
With a reliable reference system in hand, the capacity for thiols
1−5 to synergize with meropenemwas next investigated. Table 1
shows the synergy data of the twomost potent thiols 3 and 4 (see
Table S2 for complete activity data for compounds 1−5).
Captopril 1 exhibited moderate to weak synergy at a
concentration of 64 μg/mL while thiosalicylic acid 2 displayed
no appreciable synergy when tested at the same concentration.
By comparison, when administered at 64 μg/mL, thiols 3 and 4
significantly lowered the MIC of meropenem against all the
MBL-producing isolates tested. The activity of compound 5 was
also promising but interestingly was limited to only the two
Klebsiella strains tested. Thiols 3−5 have previously been shown
to be more potent MBL inhibitors than compounds 1 and 2 in
biochemical enzyme inhibition assays,17,18,21,23 and our MIC
synergy results follow the same trend. Notably, for compounds 3
and 4, we observed broad-spectrum and, in some cases, potent
synergistic activity with meropenem against the MBL-producing
isolates evaluated. Building on the encouraging results of the
preliminary synergy assays (carried out at fixed thiol concen-
tration of 64 μg/mL), we next performed a series of
checkerboard synergy assays in which the MIC of meropenem
was determined at varying concentrations of inhibitors 1−5.
Such an approach provides for a better picture of the synergistic
relationship between the two combined agents and allows for
determination of the fractional inhibitory concentration (FIC)
index. Briefly, FIC values are calculated by adding the following
two fractional values: (MIC of compound A in combination/
MIC of compound A alone) + (MIC of compound B in
combination/MIC of compound B alone). In general, an FIC
index value <0.5 is regarded as an indication of synergy.28 A
complete overview of all the checkerboard assays performed as
well as the corresponding FIC index values is provided in the
Supporting Information. Among the MBL-expressing strains
used, the two Klebsiella isolates were most effectively resensitized
to themeropenemwhen administered in combination with thiols
3−5. Of particular note, compounds 3 and 4 were both found to
significantly potentiate meropenem against the IMP-28 produc-
ing Klebsiella strain tested with FIC values ≤0.07 and ≤0.13,
respectively (based on the concentrations tested; see Table 1 for
checkerboard FIC data of thiols 3 and 4 and Supporting
Information for graphical representation of checkerboard
assays).
Thiols are well-known for their tendency to form homo- or
heterodisulfides in biological systems. Such reactivity is of special
importance in the case of thiol-based MBL inhibitors such as
compounds 1−5 as it has been reported that in their disulfide
form their activity is significantly reduced.18 In this regard, we
selected compounds 3−5 as the three most active thiols from our
synergy assays and monitored their conversion to the
corresponding disulfides under the assay conditions used. Thiols
3−5 were thus incubated in Mueller-Hinton broth at 37 °C, and
sample aliquots were analyzed at time points ranging from 0 to 8
h. As shown in Figure 2, thiols 3 and 4 were found to form their
corresponding disulfides (6 and 7, respectively) with half-lives of
ca. 5 h. By comparison, thiol 5 was oxidized to 8 more rapidly
with a half-life in the range of minutes which may also explain its
lower level of synergy relative to 3 and 4. Disulfides 6−8 were
synthesized for use as reference compounds in the stability assays
Figure 1. Thiol-based MBL inhibitors and disulfides evaluated for
synergy with meropenem and cefoperazone in the current study.
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and were evaluated for their synergy with meropenem against the
two most susceptible Klebsiella isolates identified (Table S20).
The three disulfides exhibited very low levels of synergy relative
to that of the corresponding free thiols. The slight synergy
observed for these disulfides may in fact be attributable to a
reductive process carried out by the bacteria themselves to
release a small amount of the more active thiol. Many bacteria
contain redox active enzymes capable of disulfide reduction both
in cytoplasm and periplasmic space.29
The superior synergistic activity and relative stability of thiols 3
and 4 prompted us to further characterize their zinc binding
abilities using isothermal titration calorimetry (ITC). To do so, a
solution of zinc chloride was titrated into the sample well
containing either 3 or 4 (both 3 and 4 were both to be found
stable in the buffer conditions used for the ITC experiments) and
the heat of binding was monitored. In this way, a number of
thermodynamic binding parameters are revealed including Kd
(dissociation constant),ΔH (enthalpy),ΔG (Gibbs free energy),
and ΔS (entropy). As shown in Figure 3, compounds 3 and 4
exhibited high affinities for Zn2+ with Kd values of 9.8 and 20.0
μM, respectively. Also of note was the lack of any measurable
binding interaction when zinc chloride was titrated into solutions
of disulfides 6 and 7. The zinc binding abilities of the reference
compounds EDTA and 1,10-phenanthroline were also assessed
using ITC showing a strong interaction (Figures S3 and S4). The
results of these ITC studies correlate well with the synergy data
obtained and suggest that zinc binding may be a useful predictor
for a compound’s ability to resensitize MBL-expressing
organisms to beta-lactam antibiotics. Furthermore, the relative
ease with which ITC can be used to assess zinc binding by small
molecules may make it a complementary technique for
identifying new lead compounds capable of effectively inhibiting
MBLs.
■ CONCLUSION
While small molecule thio-carbonyl compounds have previously
been shown to inhibit various MBLs, their ability to synergize
with β-lactam antibiotics in overcoming MBL-associated
resistance has not been extensively studied.We here demonstrate
a significant level of synergism between meropenem and a series
of thiols, most notably thiomandelic acid 3 and 2-merpto-3-
phenylpropionic acid 4. Combinations of meropenemwith 3 or 4
exhibit antibacterial activity against a number of Gram-negative
bacteria expressing different MBLs including IMP, NDM, and
VIM. Given the high degree of active site heterogeneity among
the different types of MBL enzymes,11 designing an inhibitor
with potent inhibitory activity toward several types of MBL is
challenging. In this light, thiomandelic acid 3 is unique given its
ability to inhibit a range of MBLs and, as shown in the present
study, its capacity to resensitize MBL-expressing Gram-negative
isolates to meropenem, an important β-lactam antibiotic of last
resort. In addition, ITC studies showed thiols 3 and 4 to be
effective zinc chelators with low-micromolar Kd values
supporting the proposed mechanism of action for these
compounds. In this regard, ITC may provide a useful means of
(pre)screening for zinc-binding MBL inhibitors. While com-
pounds 3 and 4 exhibit potent synergy with meropenem, their
propensity to oxidize and likely ability to interact with free zinc
and other metallo proteins precludes their use as clinical MBL
inhibitors. In this regard, MBL inhibitors employing free thiols as
zinc chelating groups are more likely to be of value as tool
compounds for biochemical studies involving MBLs. Optimized
analogues or other classes of MBL inhibitors capable of
overcoming such pharmacokinetic hurdles present a key
objective in the continued fight against antibiotic resistance.
■ MATERIALS AND METHODS
Materials. Potassium thioacetate was purchased from
Combi-Blocks Inc. (San Diego, CA USA). Thiosalicylic acid
was purchased from Fisher Scientific (Waltham, MA USA).
Other reagents, including captopril, 2-bromoacetophenone, S-
mandelic acid, and L-phenylalanine, were purchased from Sigma-
Aldrich company.
Synthesis. Among the thiols selected for investigation,
captopril 1 and thiosalicylic acid 2 were commercially available
while compounds 3−5 required preparation via previously
reported synthetic routes.21,30−32 Briefly, compound 3 was
synthesized via esterification of S-mandelic acid which was
Table 1. MIC (μg/mL) of Meropenem (Mer) and Ceferazone (Cef) Tested Alone or in Combination with Thiol MBL-Inhibitors 3
and 4
isolates Mer Cef Mer + 3a Cef + 3 Mer + 4 Cef + 4 Mer + EPb Cef + EPb
K. pneumoniae RC10 (KPC-2) >128 >256 128 >256 >128 >256 >128c >256c
K. pneumoniae RC 45 (OXA-48) 64 >256 64 >256 64 >256 16d >256d
K. pneumoniae RC51 (VIM-1) 64/32 >256 0.5 (≥128,e
≤0.27f)
256 1 (32,e ≤0.38f) >256 ≤0.5c 8c









E. coli RC89 (NDM-1) 128/64 >256 16 (8e) >256 16 (8e) >256 ≤1c >256c
P. aeruginosa RC60 (VIM) 32 128 4 (8,e ≤0.38f) 16 (8,e ≤0.5f) 8 (4e) 16 (8,e ≤0.5f) 0.5c 8c
P. aeruginosa JS80 (IMP) 64 256 8 (8e) 8 (32,e ≤0.38f) 8 (8,e ≤0.5f) 16 (16,e ≤0.25f) 4g 4g
K. pneumoniaeRC21 (VIM-1) 64/32 >256 0.5 (64,e ≤0.19f) >256 1 (32,e ≤0.38f) >256 ≤0.5g ≤2g
E. aerogenes RC22 (VIM-1) 32/16 >256 0.5 (64,e ≤0.25f) >256 1 (16,e ≤0.38f) >256 ≤0.25g 64g
K. pneumoniaeRC48 (VIM-1) >128/128 >256 4 (>32,e ≤0.38f) >256 8 (16,e ≤0.5f) >256 ≤1g ≤2g
K. pneumoniae JS22 (NDM-1) 32/16 >256 8 (4e) >256 2 (16,e ≤0.38f) >256 ≤0.5g >256g
K. pneumoniae JS177 (NDM-1) 16/8 >256 4 (4e) >256 1 (8e) >256 ≤0.25g >256g
K. pneumoniae JS37 (NDM-1) 64/32 >256 16 (4e) >256 16 (4e) >256 ≤1g >256g
P. aeruginosa M-120 (IMP) <1 128/64 n.d. 2 (32,e ≤0.25f) n.d. 4 (16,e ≤0.38f) n.d. 4 (32)d
aThiols 3 and 4 added at 64 μg/mL. None of the thiols inhibited growth at this concentration when tested alone. bEP = EDTA/1,10-phenanthroline
mixture. cEP mixture applied at 16 μg/mL EDTA and 1 μg/mL 1,10-phenanthroline. dEP mixture applied at 64 μg/mL EDTA and 4 μg/mL 1,10-
phenanthroline. eFold reduction of MIC. Reduction of MIC greater than 8-fold shown in bold. fLowest FIC measured (FIC < 0.5 regarded as an
indication of synergy). gEP mixture applied at 32 μg/mL EDTA and 2 μg/mL 1,10-phenanthroline.
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followed bymesylation of the hydroxyl group. Substitution of the
tosylate ester with thioacetate anion followed by acidic hydrolysis
furnished 3.30 For the synthesis of compound 4, L-phenylalanine
was converted to its corresponding α-bromocarboxylic acid
through a sodium nitrite mediated halo-deamination reaction,
which was subsequently reacted with potassium thioacetate to
afford S-acetyl derivative of 4. Basic hydrolysis of the latter
intermediate led to the final product 4.31,32 Thioacetophenone 5
was prepared via a two-step procedure involving thiolation of α-
bromoacetophenone with potassium thioacetate followed by a
basic hydrolysis.21 In addition, disulfides 6−833−35 were readily
prepared by reacting the corresponding thiol with iodine in
water/acetonitrile.36
MIC Determinations and Synergy Assays. The anti-
bacterial activity of compounds 1−5 was evaluated alone and in
combination with meropenem against a panel of β-lactamase
producing Gram-negative bacteria including K. pneumoniae
RC10 (KPC-2), K. pneumoniae RC 45 (OXA-48), K. pneumoniae
RC51 (VIM-1), K. pneumoniae JS265 (IMP-28), E. coli RC89
(NDM-1), P. aeruginosa RC60 (VIM), P. aeruginosa JS80 (IMP),
K. pneumoniae RC21 (VIM-1), E. aerogenes RC22 (VIM-1),
K. pneumoniae RC48 (VIM-1), K. pneumoniae JS22 (NDM-1),
K. pneumoniae JS177 (NDM-1), K. pneumoniae JS37 (NDM-1),
and P. aeruginosaM-120 (IMP). The CLSI guidelines were used
to determine minimum inhibitory concentrations (MICs).
Starting from glycerol stocks, bacterial strains were cultured on
blood agar plates and incubated at 37 °C. A single colony was
then transferred to tryptic soy broth (TSB) and incubated with
shaking at 37 °C until the optical density of the bacterial
suspension reached a level equivalent to the 0.5 McFarland
standard. The suspension was then diluted to 106 CFU/mL in
Mueller-Hinton broth (MHB). Using polypropylene microtiter
plates, the wells of the first row received 50 μL of the test
compounds dissolved in MHB and were subjected to serial
dilution. Finally, 50 μL of the bacterial suspension was added,
and the plates were sealed and incubated at 37 °C with constant
shaking (at 600 rpm). The next morning, the plates were
inspected for visible bacterial growth.
Synergy betweenmeropenem (or cefoperazone) and thiols 1−
5 was evaluated as follows: To the top row of a 96 well plate, 100
μL of a solution of meropenem at 4× MIC was added. 50 μL
aliquots of this solution were serially diluted down each row to
achieve a range of decreasing meropenem concentrations. Next,
thiols 1−5 (50 μL aliquots) were added to the wells to provide a
concentration range of 128 to 16 μg/mL. The relevant bacterial
suspension (100 μL/well) was finally added to each well to give a
final concentration of thiols 1−5 ranging from 64 to 8 μg/mL.
The plates were sealed and incubated overnight at 37 °C. MICs
were determined the next morning by visual inspection and used
in calculating fractional inhibitory concentration index (FICI)
values. As a standard MBL inhibitor cocktail, a 16:1 (w/w)
mixture of ethylenediaminetetraacetic acid disodium salt-
phenanthroline (EP) was also used. The MIC of the EP mixture
was first determined against each strain so that sub-MIC
concentrations could be used for synergy assays. All the assays
were performed in duplicates. Tables S3−S17 provide a graphical
representation of the checkerboard assays.
Stability Analysis. To prepare calibration curves for thiols
3−5 and the corresponding disulfides 6−8, each compound was
dissolved in DMSO to prepare a stock solution (10 mg/mL) that
was then immediately diluted in Mueller-Hinton broth (MHB)
to reach concentrations ranging from 1 to 256 μg/mL. The
samples were then processed as follows: To precipitate undesired
media components, the sample solutions were diluted with
acetonitrile (1:3 v/v), vortexed for 10 s, and centrifuged at 10 000
rpm for 10 min. The supernatant was retained and stored at −20
°C until HPLC analysis. Samples were analyzed by analytical RP-
HPLC using a Phenomenex Gemini C-18 110A column (250 ×
4.60 mm, 5 μm) at a flow rate of 1 mL/min, and their UV
absorbances were detected at 214 nm. For the analysis of
compounds 4, 5, 7, and 8, the gradient started with 0% buffer B
(95% acetonitrile, 0.1% TFA) and 100% buffer A (5%
acetonitrile, 0.1% TFA) increasing to 50% buffer B over 5 min
followed by an increase to 100% buffer B over 10 min and
maintenance at 100% buffer B for 3 min. The buffer gradient was
then returned to 0% buffer B in 2 min and maintained at 0% for
an additional 5 min to re-equilibriate the system. For the analysis
of compounds 3 and 6, the gradient started with 0% of buffer B,
increased to 50% buffer B over 5 min, and then to 90% buffer B
over 8 min followed by a final increase to 100% buffer B over 1
min. After 1 min at 100% buffer B, the gradient returned to 0%
Figure 2. Time-dependent oxidation of thiols 3−5 to corresponding
disulfides 6−8 by incubation in Mueller-Hinton broth at 37 °C.
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buffer B over 2 min and was maintained at 0% for 3 min to re-
equilibriate the system. The calibration curves were linear from 2
to 256 μg/mL for compounds 3−6 and from 1.6 to 200 μg/mL
for compounds 7 and 8with r2 > 0.990 in all the cases. Due to the
relatively short half-life of compound 5 in MHB, the medium
needed to be supplemented with 5.0 mM TCEP to obtain a
suitable calibration curve.
To assess the half-lives of thiols 3−5 in MHB, each compound
was dissolved in MHB (200 μg/mL) and incubated at 37 °C. At
time points of 0, 0.5, 1, 2, 4, and 8 h, 100 μL aliquots of each
sample were taken and subjected to the same processing
described above for the standards prior to HPLC analysis.
Isothermal Titration Calorimetry. ITC experiments were
performed using a MicroCal Auto-ITC200 instrument (Mal-
vern). The test compounds and zinc chloride were dissolved in
Tris−HCl buffer (20 mM, pH 7.0) and degassed using a
sonication bath (10 min) before running the experiments. The
zinc chloride solution was titrated into a solution of 3, 4, 6, 7,
EDTA, or 1,10-phenanthroline (see Table 2 for specific
concentrations used) over 26 aliquots of 1.5 μL (except the
first injection which was 0.5 μL) with 120 s between injections.
All the experiments were performed at 25 °C in triplicate with
reference power set at 2.0 μcal/s. The generated peaks were
integrated using Origin 7.0 software. The error for all the
reported thermodynamic parameters was estimated through




The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acsinfecdis.7b00094.
Spectral characterization of compounds 3−8 including 1H
NMR, 13C NMR, and high-resolution mass spectrometry
data; tables of antibiotic susceptibility and checkerboard
synergy assays using meropenem or cefoperazone
combined with thiols 1−5 or disulfides 6−8 (Tables
S1−S20); ITC thermograms of binding interactions
between Zn2+ and thiols 3 and 4, disulfides 6 and 7,
1,10-phenanthroline, and EDTA (Figures S1−S9) (PDF)
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Figure 3. ITC thermograms for binding of Zn2+ by thiols 3 (A) and 4 (B). A solution of zinc chloride (2.0 mM) was titrated into the sample cell
containing thiol 3 or 4 (0.2 mM). Thermodynamic parameters shown based on triplicate binding assays and reported as mean± SE. Errors estimated via
Monte Carlo simulations using the error of individual experiments.
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